142 related articles for article (PubMed ID: 23610115)
21. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
[TBL] [Abstract][Full Text] [Related]
22. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib-Sunitinib Sequence: The Jury Is Out.
Albiges L; Escudier B
Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
[No Abstract] [Full Text] [Related]
24. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
[No Abstract] [Full Text] [Related]
25. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
[TBL] [Abstract][Full Text] [Related]
27. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib-induced tuberculosis reactivation.
Teo M; O'Connor TM; O'Reilly SP; Power DG
Onkologie; 2012; 35(9):514-6. PubMed ID: 23007150
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
[TBL] [Abstract][Full Text] [Related]
30. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
Bellesoeur A; Carton E; Mir O; Groussin L; Blanchet B; Billemont B; Clerc J; Goldwasser F
Invest New Drugs; 2014 Jun; 32(3):569-72. PubMed ID: 24399106
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
[No Abstract] [Full Text] [Related]
32. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
33. Sorafenib: osteonecrosis of the jaw.
Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
[No Abstract] [Full Text] [Related]
34. Perforating folliculitis-like reaction related to sorafenib.
Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
[No Abstract] [Full Text] [Related]
35. Psychotic disorder induced by a combination of sorafenib and BAY86-9766.
Kuo YL; Yang YK; Cheng HC; Yen CJ; Chen PS
Gen Hosp Psychiatry; 2014; 36(4):450.e5-7. PubMed ID: 24773940
[TBL] [Abstract][Full Text] [Related]
36. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
[No Abstract] [Full Text] [Related]
37. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
[TBL] [Abstract][Full Text] [Related]
38. [Side effects of sorafenib and countermeasures].
Nakayama M; Arai Y; Nishimura K
Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
Okada K; Nakano Y; Yamasaki K; Nitani C; Fujisaki H; Hara J
Cancer Med; 2016 Aug; 5(8):1947-9. PubMed ID: 27264843
[TBL] [Abstract][Full Text] [Related]
40. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
